Sign in

Mathieu Choufani

@mchoufani.bsky.social
18 followers 23 following 6 posts

PGY-1 @VCU_IMres. MD graduate 2023 - @AUB_lebanon 🇱🇧. BA - Philosophy 2019 🌱. Rheumatology clinical research @BrighamWomens.

PostsRepliesMedia
Mathieu Choufani @mchoufani.bsky.social · 01/04/2025
Excited to share our latest publication on demographic & geographic diversity in axial spondyloarthritis drug trials! We analyzed 59 trials (16,000+ participants) since 2000. Big thanks to the team @wissamghusn.bsky.social @spondymd.bsky.social @joergermann pubmed.ncbi.nlm.nih.gov/40089303/
pubmed.ncbi.nlm.nih.gov
Diversity in Axial Spondyloarthritis Drug Trials: Enrollment by Sex, Race, Ethnicity, and Geographic Region - PubMed
The enrollment of women in axSpA drug trials largely reflects disease demographics. Race and ethnicity reporting has improved over time. While participation of Asian, American Indian/Alaska Native and...
141
Mathieu Choufani @mchoufani.bsky.social · 16/12/2024
Thrilled to share our latest publication in Current Rheumatology Reports on the importance of clinical practice guidelines and the key priorities for updating the next edition of the ACR/SAA/SPARTAN axial spondyloarthritis guideline! #SPARTAN #axSpA link.springer.com/article/10.1...
link.springer.com
Updating the 2019 ACR/SAA/SPARTAN Recommendations for the Treatment of Ankylosing Spondylitis and Nonradiographic Axial Spondyloarthritis (SPARTAN 2024 Annual Meeting Proceedings) - Current Rheumatolo...
Purpose of Review Since the publication of the 2019 American College of Rheumatology/Spondylitis Association of America/Spondyloarthritis Research and Treatment Network (ACR/SAA/SPARTAN) treatment rec...
030